Neurocrine Biosciences
Tracked across 3 events · 59 articles · First seen Apr 01, 2026 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio in endocrinology and rare diseases with the addition of VYKAT XR. This acquisition is expected to accelerate revenue growth and diversify its product offerings.
Apr 06, 2026 · 6 articles
Business
Impact: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio into metabolic disorders with the addition of VYKAT XR. This deal is seen as a strategic entry into the metabolic disease market.
Apr 06, 2026 · 6 articles
Business
Impact: Neurocrine Biosciences, Inc. is the proposed acquirer of MiNK Therapeutics.
Apr 01, 2026 · 47 articles
ERGEN INTELLIGENCE
Track Neurocrine Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard